Abstract
BackgroundCutaneous immune-related adverse events (cirAEs) are the most common form of immune-related adverse events after immune-checkpoint inhibitor (ICI) treatment, affecting up to 40% of ICI recipients and ranging in severity...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
